Physician profile
Julia Leigh Jones
NPI 1225024854
$45,833.08
in general payments reported to CMS, 2019-2025
61 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $6,721 · 2021: $2,745 · 2022: $1,857 · 2023: $2,350 · 2024: $1,216 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,551.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30,379.16 | 2019-2024 | Aimovig, Uplizna |
| Novartis Pharmaceuticals Corporation | $1,771.65 | 2019-2025 | |
| Genzyme Corporation | $1,617.95 | 2019-2023 | |
| Abbvie INC. | $1,540.09 | 2021-2025 | |
| Pfizer INC. | $1,387.57 | 2022-2025 | |
| Biogen, INC. | $1,002.10 | 2019-2023 | Vumerity, Avonex |
| Lilly USA, LLC | $904.25 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Lundbeck LLC | $686.22 | 2020-2025 | Vyepti |
| Emd Serono, INC. | $569.92 | 2019-2024 | Mavenclad |
| Allergan, INC. | $549.54 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $530.61 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $434.13 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $370.33 | 2019-2025 | Ajovy |
| Horizon Therapeutics Plc | $345.21 | 2022-2023 | Uplizna |
| Argenx US, INC. | $300.68 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.